Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company

Everest Medicines Appoints Rogers Yongqing Luo as New CEO

Fineline Cube Sep 19, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers...

Drug Policy / Regulatory

Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage

Fineline Cube Sep 16, 2022

Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...

Company Deals

Shenzhen Vivolight Raises RMB 100 Million in Series D1 Financing for Laser Therapy Development

Fineline Cube Sep 16, 2022

China-based laser diagnosis and treatment specialist Shenzhen Vivolight Medical Device & Technology Co., Ltd reportedly...

Company Digital

Best Covered Raises RMB 100 Million in Series A+ Funding for Cognitive Impairment Solution

Fineline Cube Sep 16, 2022

Shanghai-based digital cognitive impairment solution provider Best Covered reportedly raised RMB 100 million (USD 14.2...

Company Deals Policy / Regulatory

US Blocks Asymchem’s Acquisition of Snapdragon Chemistry

Fineline Cube Sep 16, 2022

US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...

Company Drug

Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22

Fineline Cube Sep 16, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...

Policy / Regulatory

CDE Issues Guidelines for Anti-Tumor ADC Clinical Development

Fineline Cube Sep 16, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company

Eli Lilly Announces Global C-Suite Changes, New Leadership in China

Fineline Cube Sep 16, 2022

US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...

Company Policy / Regulatory

China’s Policy Shifts Medical Device Procurement Toward Domestic Products

Fineline Cube Sep 16, 2022

Local government policies in China have begun to direct public hospitals to prioritize the procurement...

Company

Antengene Expands to Australia with New Melbourne Office

Fineline Cube Sep 16, 2022

China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne,...

Company Deals

Great Bay Bio Completes USD 15M Pre-Series B Financing to Advance AI Bioprocessing Platforms

Fineline Cube Sep 15, 2022

Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD...

Company Deals

Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution

Fineline Cube Sep 15, 2022

China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with...

Company Deals

Suzhou Jade Biomedical Secures USD 10 Million Series B Financing

Fineline Cube Sep 15, 2022

China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B...

Company Deals

Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding

Fineline Cube Sep 15, 2022

Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...

Company Deals

Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center

Fineline Cube Sep 15, 2022

China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...

Company Deals

Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion

Fineline Cube Sep 15, 2022

Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...

Company Drug

Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance

Fineline Cube Sep 15, 2022

China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...

Company Deals

Bide Pharmatech Set for IPO on Shanghai’s STAR Market

Fineline Cube Sep 15, 2022

Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...

Drug Policy / Regulatory

NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Sep 15, 2022

The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...

Company Drug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

Fineline Cube Sep 15, 2022

Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...

Posts pagination

1 … 669 670 671 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.